Drug Profile
Research programme: adenosine A2A receptor antagonists - Gilead Sciences
Latest Information Update: 15 Mar 2010
Price :
$50
*
At a glance
- Originator CV Therapeutics
- Developer Gilead Sciences
- Class
- Mechanism of Action Adenosine A2A receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Substance-related disorders
Most Recent Events
- 17 Apr 2009 CV Therapeutics has been acquired and merged into Gilead Sciences